These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32887526)
21. NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain. Smith KE; Boules M; Williams K; Richelson E Behav Brain Res; 2012 Jun; 232(1):93-7. PubMed ID: 22504145 [TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. García-Garayoa E; Allemann-Tannahill L; Bläuenstein P; Willmann M; Carrel-Rémy N; Tourwé D; Iterbeke K; Conrath P; Schubiger PA Nucl Med Biol; 2001 Jan; 28(1):75-84. PubMed ID: 11182567 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of a (18)F-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors. Lang C; Maschauer S; Hübner H; Gmeiner P; Prante O J Med Chem; 2013 Nov; 56(22):9361-5. PubMed ID: 24160350 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues. Fanelli R; Besserer-Offroy É; René A; Côté J; Tétreault P; Collerette-Tremblay J; Longpré JM; Leduc R; Martinez J; Sarret P; Cavelier F J Med Chem; 2015 Oct; 58(19):7785-95. PubMed ID: 26348111 [TBL] [Abstract][Full Text] [Related]
25. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. Maina T; Nikolopoulou A; Stathopoulou E; Galanis AS; Cordopatis P; Nock BA Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1804-14. PubMed ID: 17594090 [TBL] [Abstract][Full Text] [Related]
27. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461 [TBL] [Abstract][Full Text] [Related]
28. CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer. Erdmann S; Niederstadt L; Koziolek EJ; Gómez JDC; Prasad S; Wagener A; von Hacht JL; Reinicke S; Exner S; Bandholtz S; Beindorff N; Brenner W; Grötzinger C Theranostics; 2019; 9(22):6719-6733. PubMed ID: 31588246 [No Abstract] [Full Text] [Related]
29. Development of [ Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537 [TBL] [Abstract][Full Text] [Related]
30. Neurotensin NTS Steele FF; Whitehouse SC; Aday JS; Prus AJ Brain Res; 2017 Mar; 1658():31-35. PubMed ID: 28089664 [TBL] [Abstract][Full Text] [Related]
31. Imaging Neurotensin Receptor in Prostate Cancer With Deng H; Wang H; Zhang H; Wang M; Giglio B; Ma X; Jiang G; Yuan H; Wu Z; Li Z Mol Imaging; 2017; 16():1536012117711369. PubMed ID: 28849698 [TBL] [Abstract][Full Text] [Related]
32. Design, Synthesis, and Biological Evaluation of Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911 [TBL] [Abstract][Full Text] [Related]
33. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Bruehlmeier M; Garayoa EG; Blanc A; Holzer B; Gergely S; Tourwé D; Schubiger PA; Bläuenstein P Nucl Med Biol; 2002 Apr; 29(3):321-7. PubMed ID: 11929702 [TBL] [Abstract][Full Text] [Related]
34. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor. Wu Z; Li L; Liu S; Yakushijin F; Yakushijin K; Horne D; Conti PS; Li Z; Kandeel F; Shively JE J Nucl Med; 2014 Jul; 55(7):1178-84. PubMed ID: 24854793 [TBL] [Abstract][Full Text] [Related]
35. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor. Deng H; Wang H; Wang M; Li Z; Wu Z Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008 [TBL] [Abstract][Full Text] [Related]
36. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
37. Catabolism of neurotensins. Implications for the design of radiolabeling strategies of peptides. Schubiger PA; Allemann-Tannahill L; Egli A; Schibli R; Alberto R; Carrel-Rémy N; Willmann M; Bläuenstein P; Tourwé D Q J Nucl Med; 1999 Jun; 43(2):155-8. PubMed ID: 10429510 [TBL] [Abstract][Full Text] [Related]
38. Structure-based exploration of an allosteric binding pocket in the NTS1 receptor using bitopic NT(8-13) derivatives and molecular dynamics simulations. Kling RC; Burchardt C; Einsiedel J; Hübner H; Gmeiner P J Mol Model; 2019 Jun; 25(7):193. PubMed ID: 31209646 [TBL] [Abstract][Full Text] [Related]
39. Expression of neurotensin receptor-1 (NTS Morgat C; Brouste V; Chastel A; Vélasco V; Macgrogan G; Hindié E Breast Cancer Res Treat; 2021 Dec; 190(3):403-413. PubMed ID: 34596798 [TBL] [Abstract][Full Text] [Related]
40. Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog. Tétreault P; Besserer-Offroy É; Brouillette RL; René A; Murza A; Fanelli R; Kirby K; Parent AJ; Dubuc I; Beaudet N; Côté J; Longpré JM; Martinez J; Cavelier F; Sarret P Eur J Pharmacol; 2020 Sep; 882():173174. PubMed ID: 32534076 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]